Company Fundamentals - Segments

Company Name Kalbe Farma Tbk PT (KLBF.JK)

Country of Exchange Indonesia
Country of Headquarters Indonesia
TRBC Industry Group Pharmaceuticals
CF Template IND
Consolidation Basis Consolidated
Scaling Millions
Period Annual
Export Date 16-01-2023
Statement Data 2017 2018 2019 2020 2021
Period End Date 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Standardized Currency IDR IDR IDR IDR IDR
Segments - Business Line By Segment (Currency: As Reported)
Field Name TRBC 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
622110, 325412,
Prescription Pharmaceutical 325411
Cost of Revenues - Total 2,053,115 2,204,804 2,414,609 2,324,491 2,699,596
External Revenue 4,689,684 4,821,801 5,166,127 4,983,939 5,719,423
Gross Profit 2,636,568 2,616,997 2,751,518 2,659,448 3,019,826
532283, 456191,
Consumer Health 325412, 325411
Cost of Revenues - Total 1,513,884 1,604,070 1,558,094 1,578,903 1,484,373
External Revenue 3,420,188 3,569,154 3,470,978 3,632,819 3,622,825
Gross Profit 1,906,303 1,965,084 1,912,884 2,053,916 2,138,452
Nutritionals 456191, 311514
Cost of Revenues - Total 2,616,109 2,874,220 3,046,027 3,135,802 3,477,372
External Revenue 6,102,161 6,307,870 6,620,644 6,743,472 7,166,475
Gross Profit 3,486,052 3,433,650 3,574,617 3,607,671 3,689,102
Distribution and Logistics 541614, 424210
Cost of Revenues - Total 4,186,728 4,543,287 5,371,278 5,827,137 7,316,069
External Revenue 5,970,088 6,375,482 7,375,727 7,752,425 9,752,472
Gross Profit 1,783,360 1,832,195 2,004,449 1,925,288 2,436,403
Total
Cost of Revenues - Total 10,369,837 11,226,380 12,390,009 12,866,333 14,977,410
External Revenue 20,182,120 21,074,306 22,633,476 23,112,655 26,261,195
Gross Profit 9,812,283 9,847,926 10,243,468 10,246,322 11,283,784
Company Fundamentals - Segments
Company Name Kalbe Farma Tbk PT (KLBF.JK)
Country of Exchange Indonesia
Country of Headquarters Indonesia
TRBC Industry Group Pharmaceuticals
CF Template IND
Consolidation Basis Consolidated
Scaling Millions
Period Annual
Export Date 16-01-2023
Statement Data 2017 2018 2019 2020 2021
Period End Date 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Standardized Currency IDR IDR IDR IDR IDR
Segments - Business Line By Statement Item (Currency: As Reported)
Field Name TRBC 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Gross Profit 9,812,283 9,847,926 10,243,468 10,246,322 11,283,784
Consumer Health 532283, 456191, 1,906,303 1,965,084 1,912,884 2,053,916 2,138,452
325412, 325411
Distribution and Logistics 541614, 424210 1,783,360 1,832,195 2,004,449 1,925,288 2,436,403
Nutritionals 456191, 311514 3,486,052 3,433,650 3,574,617 3,607,671 3,689,102
622110, 325412,
Prescription Pharmaceutical 325411 2,636,568 2,616,997 2,751,518 2,659,448 3,019,826
External Revenue 20,182,120 21,074,306 22,633,476 23,112,655 26,261,195
532283, 456191,
Consumer Health 325412, 325411 3,420,188 3,569,154 3,470,978 3,632,819 3,622,825
Distribution and Logistics 541614, 424210 5,970,088 6,375,482 7,375,727 7,752,425 9,752,472
Nutritionals 456191, 311514 6,102,161 6,307,870 6,620,644 6,743,472 7,166,475
Prescription Pharmaceutical 622110, 325412, 4,689,684 4,821,801 5,166,127 4,983,939 5,719,423
325411
Cost of Revenues - Total 10,369,837 11,226,380 12,390,009 12,866,333 14,977,410
Consumer Health 532283, 456191, 1,513,884 1,604,070 1,558,094 1,578,903 1,484,373
325412, 325411
Distribution and Logistics 541614, 424210 4,186,728 4,543,287 5,371,278 5,827,137 7,316,069
Nutritionals 456191, 311514 2,616,109 2,874,220 3,046,027 3,135,802 3,477,372
622110, 325412,
Prescription Pharmaceutical 325411 2,053,115 2,204,804 2,414,609 2,324,491 2,699,596
Company Fundamentals - Segments
Company Name Kalbe Farma Tbk PT (KLBF.JK)
Country of Exchange Indonesia
Country of Headquarters Indonesia
TRBC Industry Group Pharmaceuticals
CF Template IND
Consolidation Basis Consolidated
Scaling Millions
Period Annual
Export Date 16-01-2023
Statement Data 2017 2018 2019 2020 2021
Period End Date 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Standardized Currency IDR IDR IDR IDR IDR
Segments - Geographic Line By Segment (Currency: As Reported)
Field Name 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Domestic
External Revenue 19,099,297
Fixed Assets - Purchased - Cash Flow 1,162,364 1,295,149 1,585,142 864,711 499,623
Revenue by Market 19,873,543 21,445,809 22,000,273 25,013,466
Total Assets 15,976,963 17,341,336 19,407,882 21,585,769 24,622,052
Export
External Revenue 1,082,823
Revenue by Market 1,200,763 1,187,668 1,112,382 1,247,728
Total
External Revenue 20,182,120
Fixed Assets - Purchased - Cash Flow 1,162,364 1,295,149 1,585,142 864,711 499,623
International Assets 0 0 0 0 0
International Sales 1,082,823
International/Export Sales 1,200,763 1,187,668 1,112,382 1,247,728
Revenue by Market 21,074,306 22,633,476 23,112,655 26,261,195
Total Assets 15,976,963 17,341,336 19,407,882 21,585,769 24,622,052
Company Fundamentals - Segments
Company Name Kalbe Farma Tbk PT (KLBF.JK)
Country of Exchange Indonesia
Country of Headquarters Indonesia
TRBC Industry Group Pharmaceuticals
CF Template IND
Consolidation Basis Consolidated
Scaling Millions
Period Annual
Export Date 16-01-2023
Statement Data 2017 2018 2019 2020 2021
Period End Date 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Standardized Currency IDR IDR IDR IDR IDR
Segments - Geographic Line By Statement Item (Currency: As Reported)
Field Name 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Total Assets 15,976,963 17,341,336 19,407,882 21,585,769 24,622,052
Domestic 15,976,963 17,341,336 19,407,882 21,585,769 24,622,052
Fixed Assets - Purchased - Cash Flow 1,162,364 1,295,149 1,585,142 864,711 499,623
Domestic 1,162,364 1,295,149 1,585,142 864,711 499,623
External Revenue 20,182,120
Domestic 19,099,297
Export 1,082,823
International Sales 1,082,823
International Assets 0 0 0 0 0
Revenue by Market 21,074,306 22,633,476 23,112,655 26,261,195
Domestic 19,873,543 21,445,809 22,000,273 25,013,466
Export 1,200,763 1,187,668 1,112,382 1,247,728
International/Export Sales 1,200,763 1,187,668 1,112,382 1,247,728
Company Fundamentals - Income Statement
Company Name Kalbe Farma Tbk PT (KLBF.JK)
Country of Exchange Indonesia
Country of Headquarters Indonesia
TRBC Industry Group Pharmaceuticals
CF Template IND
Consolidation Basis Consolidated
Scaling Millions
Period Annual
Export Date 16-01-2023
Statement Data 2017 2018 2019 2020 2021
Period End Date 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Standardized Currency IDR IDR IDR IDR IDR
Income Statement - Standardized (Currency: As Reported)
Field Name 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Revenues
Revenue from Goods & Services 20,182,120 21,074,306 22,633,476 23,112,655 26,261,195
Sales of Goods & Services - Net - Unclassified 20,182,120 21,074,306 22,633,476 23,112,655 26,261,195
Revenue from Business Activities - Total 20,182,120 21,074,306 22,633,476 23,112,655 26,261,195
Operating Expenses
Cost of Operating Revenue 10,622,955 11,517,284 12,793,112 13,254,991 15,333,495
Cost of Revenues - Total 10,622,955 11,517,284 12,793,112 13,254,991 15,333,495
Cost of Revenues - Unclassified 0
Amortization in Cost of Revenues 6,604.3
Depreciation in Cost of Revenues 167,308 179,445 209,580 264,392 302,392
Labor & Related Expenses including Stock-Based Compensation in Cost of Revenues 243,900 239,835 277,126 274,154 279,870
Material Expenses 4,026,373 4,367,942 4,672,393 4,870,516 5,477,655
Material Expenses - Materials, Inventory, Own Work & Utility - Unclassified 3,950,154 4,256,782 4,455,081 4,673,916 5,297,260
Changes in Inventory 76,219 111,160 217,313 196,600 180,395
Cost of Revenues - Other - Total 6,185,373 6,730,063 7,634,012 7,845,929 9,266,973
Gross Profit - Industrials/Property - Total 9,559,165 9,557,022 9,840,365 9,857,664 10,927,699
Selling, General & Administrative Expenses - Total 6,357,179 6,263,033 6,534,744 6,308,655 6,918,838
Selling, General & Administrative Expenses - Unclassified 1,571,127 1,645,694 1,618,791 1,461,884 1,643,945
Labor & Related Expenses including Stock-Based Compensation in Selling, General & Administrative Expenses 1,817,937 1,883,819 2,008,364 2,058,074 2,067,520
Research & Development Expense 607,117 477,039 511,409 441,755 487,769
Depreciation in Selling, General & Administrative Expenses 235,882 246,563 253,124 332,915 349,754
Amortization of Intangibles in Selling, General & Administrative Expenses 45,357 36,881 45,129 40,000 30,306
Operations & Maintenance (Utility) 137,412 153,578 168,525 168,197 177,509
Selling, General & Administrative Expenses - Other - Total 1,942,347 1,819,459 1,929,402 1,805,829 2,162,035
Advertising Expense 1,770,001 1,631,719 1,736,481 1,635,125 1,999,089
Property & Other Taxes 33,979 31,458 35,764 51,204 52,359
Rental Expense 123,560 132,930 133,701 97,715 100,799
Provision for Doubtful Accounts & Write-off 3,763.8
Other Operating Expense/(Income) - Net 53,212 106,770 -13,820 -41,036 -15,564
Other Operating Income - Total 30,455 35,756 49,774 48,704 27,837
Other Operating Expense 83,667 142,526 35,954 7,668.3 12,273
Operating Expenses - Total 17,033,347 17,887,087 19,314,036 19,522,610 22,236,769
Operating Profit
Operating Profit before Non-Recurring Income/Expense 3,148,773 3,187,219 3,319,440 3,590,045 4,024,425
Non-Operating Expenses
Financing Income/(Expense) - Net - Total 108,784 135,487 91,402 118,422 43,536
Interest Expense - Net of (Interest Income) -108,784 -106,128 -106,883 -75,722 -65,306
Interest Income - Non-Bank 134,914 125,787 137,938 151,559 110,792
Interest Expense - Net of Capitalized Interest 26,130 19,659 31,055 75,837 45,486
Non-Interest Financial Income/(Expense) - Total 29,359 -15,481 42,699 -21,771
Foreign Exchange Gain/(Loss) - Non-Business 29,359 -21,003 29,621 -20,022
Sale of Investments Held for Sale, Maturity & Trading - Gain/(Loss) 10,506 42,649 20,305
Non-Interest Financial Income/(Expense) - Other - Net -4,983.6 -29,571 -22,054
Sale of Tangible & Intangible Fixed Assets - Gain/(Loss) 11,661 10,368 5,974.0 23,815 15,057
Equity Earnings/(Loss) - before Taxes including Non-Recurring -16,306 -2,673.8 5,135.0 21,698 80,070
Other Non-Operating Income/(Expense) - Total -10,262 -10,080 -9,365.1 -21,716 -12,736
Normalized Pre-tax Profit 3,242,651 3,320,320 3,412,586 3,732,265 4,150,351
Non-Recurring Income/Expense
Non-Recurring Income/(Expense) - Total -98,054 0
Impairment - Tangible & Intangible Fixed Assets 98,054 0
Impairment - Goodwill 98,054 0
Pre-Tax Income
Income before Taxes 3,242,651 3,320,320 3,412,586 3,634,211 4,150,351
Taxes
Income Taxes 789,400 823,058 874,984 834,588 918,344
Income Taxes for the Year - Current 778,898 810,921 858,614 801,089 916,361
Income Taxes - Other (KFAS/NLST) - Current 778,898 810,921 858,614 801,089 916,361
Income Taxes - Deferred 10,502 12,137 16,371 33,500 1,982.5
Net Income After Tax
Net Income after Tax 2,453,251 2,497,262 2,537,602 2,799,623 3,232,008
After Tax Income/Expense
Income before Discontinued Operations & Extraordinary Items 2,453,251 2,497,262 2,537,602 2,799,623 3,232,008
Net Income before Minority Interest 2,453,251 2,497,262 2,537,602 2,799,623 3,232,008
Minority Interest 49,645 40,133 30,837 66,363 48,386
Net Income after Minority Interest 2,403,606 2,457,129 2,506,765 2,733,260 3,183,621
Net Income
Income Available to Common Shares 2,403,606 2,457,129 2,506,765 2,733,260 3,183,621
Other Comprehensive Income
Other Comprehensive Income - Starting Line 2,453,251 2,497,262 2,537,602 2,799,623 3,232,008
Other Comprehensive Income - Foreign Currency 4,155.7 10,589 -13,636 27,390 -70,735
Other Comprehensive Income - Unrealized Investment Gain/(Loss) 5,042.4 6,021.2 15,175 23,468 70,178
Other Comprehensive Income - Other -2,507.2 2,507.2
Other Comprehensive Income - Pension Related -25,601 50,951 -34,219 21,434 -16,859
Other Comprehensive Income - Income Tax 6,096.5 -12,116 8,320.9 -3,420.2 -8,599.1
Other Comprehensive Income - Net of Tax - Total -10,306 55,445 -24,359 66,365 -23,508
Comprehensive Income before Minority Interest - Total 2,442,945 2,552,707 2,513,242 2,865,987 3,208,499
Comprehensive Income - Attributable to Minority Interest - Total 50,138 42,056 30,786 68,037 48,915
Comprehensive Income - Attributable to Parent Company Equity Holders - Total 2,392,807 2,510,651 2,482,456 2,797,950 3,159,584
Share/Per Share - Basic
Net Income - Basic - including Extraordinary Items Applicable to Common - Total 2,403,606 2,457,129 2,506,765 2,733,260 3,183,621
Income available to Common excluding Extraordinary Items 2,403,606 2,457,129 2,506,765 2,733,260 3,183,621
Shares used to calculate Basic EPS - Total 46,875 46,875 46,875 46,873 46,873
EPS - Basic - including Extraordinary Items Applicable to Common - Total 51.28 52.42 53.48 58.31 67.92
EPS - Basic - excluding Extraordinary Items Applicable to Common - Total 51.28 52.42 53.48 58.31 67.92
EPS - Basic - excluding Extraordinary Items - Normalized - Total 51.28 52.42 53.48 60.40 67.92
Allocated Net Income including Extraordinary Items Applicable to Common - Issue Specific 2,403,606 2,457,129 2,506,765 2,733,260 3,183,621
Earnings Allocation Factor - Basic - Issue Specific 1.00 1.00 1.00 1.00 1.00
Shares used to calculate Basic EPS - Issue Specific 46,875 46,875 46,875 46,873 46,873
EPS - Basic - including Extraordinary Items Applicable to Common - Issue Specific 51.28 52.42 53.48 58.31 67.92
EPS - Basic - excluding Extraordinary Items Applicable to Common - Issue Specific 51.28 52.42 53.48 58.31 67.92
EPS - Basic - excluding Extraordinary Items - Normalized - Issue Specific 51.28 52.42 53.48 60.40 67.92
EPS - Basic from Discontinued Operations & Extraordinary Items 0 0 0 0 0
Comprehensive Earnings Per Share - Basic - Issue Specific 51.05 53.56 52.96 59.69 67.41
Share/Per Share - Diluted
Net Income - Diluted - including Extraordinary Items Applicable to Common - Total 2,403,606 2,457,129 2,506,765 2,733,260 3,183,621
Diluted Income available to Common excluding Extraordinary Items 2,403,606 2,457,129 2,506,765 2,733,260 3,183,621
Shares used to calculate Diluted EPS - Total 46,875 46,875 46,875 46,873 46,873
EPS - Diluted - including Extraordinary Items Applicable to Common - Total 51.28 52.42 53.48 58.31 67.92
EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total 51.28 52.42 53.48 58.31 67.92
EPS - Diluted - excluding Extraordinary Items - Normalized - Total 51.28 52.42 53.48 60.40 67.92
Allocated Diluted Net Income including Extraordinary Items Applicable to Common - Issue Specific 2,403,606 2,457,129 2,506,765 2,733,260 3,183,621
Earnings Allocation Factor - Diluted - Issue Specific 1.00 1.00 1.00 1.00 1.00
Shares used to calculate Diluted EPS - Issue Specific 46,875 46,875 46,875 46,873 46,873
EPS - Diluted - including Extraordinary Items Applicable to Common - Issue Specific 51.28 52.42 53.48 58.31 67.92
EPS - Diluted - excluding Extraordinary Items Applicable to Common - Issue Specific 51.28 52.42 53.48 58.31 67.92
EPS - Diluted - excluding Extraordinary Items - Normalized - Issue Specific 51.28 52.42 53.48 60.40 67.92
EPS - Diluted from Discontinued Operations & Extraordinary Items 0 0 0 0 0
Comprehensive Earnings Per Share - Diluted - Issue Specific 51.05 53.56 52.96 59.69 67.41
Share/Per Share - Dividends
DPS - Common - Gross - Issue - By Announcement Date 22.00 25.00 26.00 26.00 28.00
DPS - Common - Net - Issue - By Announcement Date 18.70 21.25 22.10 22.10 23.80
EBIT/EBITDA & related
Earnings before Interest & Taxes (EBIT) 3,148,773 3,187,219 3,319,440 3,590,045 4,024,425
Earnings before Interest, Taxes, Depreciation & Amortization (EBITDA) 3,603,994 3,657,888 3,834,611 4,227,353 4,713,482
Earnings before Interest, Taxes, Depreciation & Amortization (EBITDA) and Operating Lease Payments 3,727,554 3,790,818 3,968,312 4,325,068 4,814,281
Depreciation/Amortization - Income Statement
Depreciation & Amortization - Supplemental 455,221 470,669 515,170 642,166 680,414
Depreciation Expense - Total - Supplemental 403,190 426,008 462,704 597,307 652,146
Depreciation - Fin Lease Right-of-Use Assets - Total - Suppl 44,316 45,782
Amortization - Total - Supplemental 52,031 44,661 52,467 44,858 28,268
Intangible Amortization - Other - Supplemental 52,031 44,661 52,467 44,858 21,664
Amortization of Computer Software - Supplemental 41,232 33,237 39,204 33,046 9,603.9
Amortization of Brands, Patents, Trademarks, Marketing & Artistic Intangibles - Supplemental 10,799 11,424 7,883.5 6,768.0 12,060
Amortization of Capitalized Research & Development Expenses - Supplemental 5,378.9 5,044.1
Amortization of Deferred Costs - Supplemental 6,604.3
Depreciation/Amortization - Total
Depreciation, Depletion & Amortization - Total 455,221 470,669 515,170 637,308 689,056
Depreciation - Total 403,190 426,008 462,704 597,307 652,146
Amortization of Intangible Assets excluding Goodwill - Total 52,031 44,661 52,467 40,000 30,306
Amortization of Deferred Charges - Total 6,604.3
Research & Development
Research & Development Expense - Expensed & Capitalized - Total - Supplemental 607,117 477,039 511,409 441,755 487,769
Research & Development Expense - Supplemental 607,117 477,039 511,409 441,755 487,769
Labor & Related Expenses
Labor & Related Expenses - Total 2,174,785 2,248,659 2,418,327 2,476,208 2,472,846
Labor & Related Expenses - Supplemental 2,174,785 2,248,659 2,418,327 2,476,208 2,472,846
Normalized
Normalized after Tax Profit 2,453,251 2,497,262 2,537,602 2,897,676 3,232,008
Normalized Net Income from Continuing Operations 2,453,251 2,497,262 2,537,602 2,897,676 3,232,008
Normalized Net Income - Bottom Line 2,403,606 2,457,129 2,506,765 2,831,314 3,183,621
Earnings before Interest & Taxes (EBIT) - Normalized 3,133,867 3,214,192 3,305,703 3,656,542 4,085,045
Earnings before Interest, Taxes, Depreciation & Amortization (EBITDA) - Normalized 3,589,087 3,684,862 3,820,874 4,293,850 4,774,102
Other
Rental/Operating Lease Expense 123,560 132,930 133,701 97,715 100,799
Advertising Expenses - Supplemental 1,770,001 1,631,719 1,736,481 1,635,125 1,999,089
Cost of Revenue including Operation & Maintenance (Utility) - Total 10,760,368 11,670,862 12,961,637 13,423,188 15,511,004
Cost of Revenues excluding Depreciation 10,455,647 11,337,839 12,583,532 12,990,599 15,024,499
Generation Cost 10,760,368 11,670,862 12,961,637 13,423,188 15,511,004
Interest Expense 26,130 19,659 31,055 75,837 45,486
Operating Expenses 17,033,347 17,887,087 19,314,036 19,522,610 22,236,769
Selling, General & Administrative Expenses excluding Research & Development Expenses 5,750,063 5,785,995 6,023,335 5,866,899 6,431,069
Company Fundamentals - Balance Sheet
Company Name Kalbe Farma Tbk PT (KLBF.JK)
Country of Exchange Indonesia
Country of Headquarters Indonesia
TRBC Industry Group Pharmaceuticals
CF Template IND
Consolidation Basis Consolidated
Scaling Millions
Period Annual
Export Date 16-01-2023
Statement Data 2017 2018 2019 2020 2021
Period End Date 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Standardized Currency IDR IDR IDR IDR IDR
Balance Sheet - Standardized (Currency: As Reported)
Field Name 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Current Assets
Cash & Short-Term Investments 2,971,201 3,332,047 3,236,106 5,396,246 6,475,171
Cash & Cash Equivalents 2,784,706 3,153,328 3,040,487 5,207,929 6,216,248
Short-Term Investments - Total 186,495 178,719 195,619 188,316 258,923
Financial Assets - Short-Term 186,495 178,719 195,619 188,316 258,923
Loans & Receivables - Net - Short-Term 2,967,693 3,373,569 3,697,660 3,594,927 3,545,143
Trade Accounts & Trade Notes Receivable - Net 2,876,417 3,255,545 3,572,855 3,477,221 3,431,018
Trade Accounts & Trade Notes Receivable - Gross 2,898,394 3,281,251 3,600,695 3,501,113 3,455,599
Provision - Trade Accounts & Trade Notes Receivable 21,977 25,706 27,840 23,892 24,581
Receivables - Other - Total 91,276 118,024 124,805 117,706 114,125
Inventories - Total 3,557,497 3,474,587 3,737,976 3,599,746 5,087,300
Inventories - Raw Materials 897,856 848,610 860,623 757,410 1,107,325
Inventories - Work in Progress 63,548 65,228 70,520 86,824 146,617
Inventories - Finished Goods 2,551,996 2,495,634 2,692,401 2,656,915 3,730,592
Inventories - Other - Total 44,096 65,115 114,433 98,597 102,765
Prepaid Expenses - Short-Term 486,218 419,053 495,586 435,851 558,900
Other Current Assets - Total 61,341 49,032 55,163 48,562 45,696
Other Current Assets 61,341 49,032 55,163 48,562 45,696
Total Current Assets 10,043,951 10,648,288 11,222,491 13,075,332 15,712,210
Non-Current Assets
Investments - Long-Term 53,386 63,305 63,127 73,703 127,481
Financial Assets - Long-Term 53,386 63,305 63,127 73,703 127,481
Investments in Associates, Joint Ventures and Unconsolidated Subsidiaries 25,476 22,802 27,937 49,635 175,791
Receivables & Loans - Long-Term 28,499 54,345 52,685 35,247 43,576
Receivables - Other - Net - Long-Term 28,499 54,345 52,685 35,247 43,576
Property, Plant & Equipment - Net - Total 5,342,660 6,252,801 7,666,315 8,310,144 8,322,761
Property, Plant & Equipment - excluding Assets Leased Out - Net - Total 5,342,660 6,252,801 7,666,315 8,310,144 8,322,761
Land & Buildings - Net 2,902,354 3,356,649 3,498,556 4,821,042 4,920,872
Land/Improvements - Net 1,287,472 1,596,571 1,658,377 1,661,011 1,661,011
Buildings - Net 1,582,262 1,710,925 1,749,022 3,055,148 3,130,672
Leasehold Improvements - Net 32,621 49,153 91,157 104,883 129,189
Plant, Machinery & Equipment - Net 984,188 1,004,184 1,312,140 1,828,454 1,968,987
Transportation Equipment - Net 55,620 50,908 57,951 71,272 72,738
Construction in Progress - Net 1,068,142 1,494,228 2,453,566 1,054,878 903,680
Property, Plant & Equipment - Under Capital Lease - Net 3,696.3 2,118.4 51.36 0
Right of Use Tangible Assets - Total - Net 152,382 107,911
Right of Use Tangible Assets - Capital/Finance Lease - Net 152,382 107,911
Property, Plant & Equipment - Other - Net 384,279 395,623 402,001 453,387 421,312
Property, Plant & Equipment - Gross - Total 8,158,128 9,407,832 11,185,688 12,305,195 12,781,057
Property, Plant & Equipment - excluding Assets Leased Out - Gross 8,158,128 9,407,832 11,185,688 12,305,195 12,781,057
Land & Buildings - Gross 3,576,068 4,155,005 4,432,093 5,919,694 6,202,613
Land/Improvements - Gross 1,287,472 1,596,571 1,658,377 1,661,011 1,661,011
Buildings - Gross 2,232,911 2,478,592 2,641,220 4,100,259 4,337,522
Leasehold Improvements - Gross 55,685 79,842 132,496 158,425 204,081
Plant, Machinery & Equipment - Gross 2,398,322 2,546,399 2,984,348 3,654,930 3,965,769
Transportation Equipment - Gross 288,350 289,704 299,195 291,726 283,353
Construction in Progress - Gross 1,068,142 1,494,228 2,453,566 1,054,878 903,680
Property, Plant & Equipment - Under Capital Lease - Gross 6,956.3 6,983.8 410.9 0
Right of Use Tangible Assets - Total - Gross 196,875 187,966
Right of Use Tangible Assets - Capital/Finance Lease - Gross 196,875 187,966
Property, Plant & Equipment - Other - Gross 1,108,639 1,205,216 1,315,269 1,478,817 1,521,029
Property, Plant & Equipment - Accumulated Depreciation & Impairment - Total 2,815,468 3,155,030 3,519,373 3,995,050 4,458,296
Property, Plant & Equipment - excluding Assets Leased Out - Accumulated Depreciation & Impairment - Total 2,815,468 3,155,030 3,519,373 3,995,050 4,458,296
Land & Buildings - Accumulated Depreciation & Impairment 673,714 798,356 933,538 1,098,652 1,281,741
Buildings - Accumulated Depreciation & Impairment 650,649 767,667 892,198 1,045,111 1,206,850
Leasehold Improvements - Accumulated Depreciation & Impairment 23,064 30,689 41,340 53,541 74,891
Plant, Machinery & Equipment - Accumulated Depreciation & Impairment 1,414,134 1,542,215 1,672,208 1,826,476 1,996,782
Transportation Equipment - Accumulated Depreciation & Impairment 232,730 238,796 241,244 220,454 210,615
 Property, Plant & Equipment - Under Capital Lease - Accumulated Depreciation & Impairment 3,259.9 4,865.5 359.5 0
Right of Use Tangible Assets - Total/Unspecified - Accumulated Depreciation 44,493 80,056
Right of Use Tangible Assets - Capital/Finance Lease - Accumulated Depreciation 44,493 80,056
Property, Plant & Equipment - Other - Accumulated Depreciation & Impairment 724,360 809,594 913,268 1,025,430 1,099,717
Other Non-Current Assets - Total 702,696 671,224 569,619 360,221 152,086
Deferred Tax - Asset - Long-Term 155,866 131,100 123,162 85,420 91,862
Prepaid Expenses - Long-Term 223,119
Other Non-Current Assets 546,831 540,124 446,457 51,682 60,224
Intangible Assets - Total - Net 419,573 433,441 662,553 660,018 1,132,731
Intangible Assets - Gross - Total 718,331 776,860 1,051,150 1,090,536 1,583,367
Goodwill/Cost in Excess of Assets Purchased - Gross 293,280 293,280 293,280 195,226 209,684
Intangible Assets - excluding Goodwill - Gross 425,051 483,580 757,870 895,310 1,373,684
Computer Software - Intangible Assets - Gross 295,730 332,526 366,753 393,448 386,631
Brands, Patents, Trademarks, Marketing & Artistic Intangibles - Gross 129,322 151,054 391,117 501,862 987,053
Intangible Assets - Accumulated Amortization & Impairment - Total 298,758 343,419 388,597 430,518 450,636
Total Non-Current Assets 6,572,289 7,497,918 9,042,236 9,488,968 9,954,426
Total Assets
Total Assets 16,616,239 18,146,206 20,264,727 22,564,300 25,666,635
Current Liabilities
Trade Accounts Payable & Accruals - Short-Term 1,430,582 1,590,998 1,685,324 1,722,334 2,378,533
Trade Accounts & Trade Notes Payable - Short-Term 1,108,551 1,289,898 1,215,860 1,240,386 1,667,596
Accrued Expenses - Short-Term 322,031 301,100 469,464 481,949 710,937
Short-Term Debt & Current Portion of Long-Term Debt 173,389 97,406 169,157 369,264 93,646
Short-Term Debt & Notes Payable 168,775 69,155 149,638 220,500 0
Current Portion of Long-Term Debt including Capitalized Leases 4,614.3 28,251 19,519 148,764 93,646
Current Portion of Long-Term Debt excluding Capitalized Leases 2,666.7 27,103 19,424 123,843 70,000
Capitalized Leases - Current Portion 1,947.6 1,148.6 94.51 24,921 23,646
Income Taxes - Payable - Short-Term 190,793 188,122 226,517 428,878 351,590
Other Current Liabilities - Total 432,572 409,642 496,110 656,250 710,888
Other Current Liabilities 432,572 409,642 496,110 656,250 710,888
Total Current Liabilities 2,227,336 2,286,167 2,577,109 3,176,726 3,534,656
Non-Current Liabilities
Debt - Long-Term - Total 145,603 260,002 647,688 788,552 532,509
Long-Term Debt excluding Capitalized Leases 144,338 259,831 647,647 722,819 490,277
Debt - Non-Convertible - Long-Term 144,338 259,831 647,647 722,819 490,277
Capitalized Lease Obligations - Long-Term 1,264.5 170.6 40.87 65,732 42,232
Deferred Tax & Investment Tax Credits - Long-Term 636.6 129.3 241.6 2,590.6 19,572
Deferred Tax - Liability - Long-Term 636.6 129.3 241.6 2,590.6 19,572
Other Non-Current Liabilities - Total 348,632 305,313 334,106 320,350 314,019
Provisions - Long-Term 338,832 291,593 334,106 320,350 313,520
Post Employment Benefits - Pension & Other - Long-Term 338,832 291,593 334,106 320,350 313,520
Other Non-Current Liabilities 9,800.0 13,720 0 499.8
Total Non-Current Liabilities 494,872 565,444 982,036 1,111,492 866,101
Total Liabilities
Total Liabilities 2,722,208 2,851,611 3,559,144 4,288,218 4,400,757
Shareholders' Equity
Shareholders' Equity - Attributable to Parent Shareholders - Total 13,280,807 14,623,458 15,893,126 17,405,533 19,579,526
Common Equity Attributable to Parent Shareholders 13,280,807 14,623,458 15,893,126 17,405,533 19,579,526
Common Stock - Treasury/Repurchased 2,063.2 2,063.2
Common Equity - Contributed 434,633 434,633 434,633 434,633 434,633
Common Stock - Issued & Paid 468,751 468,751 468,751 468,751 468,751
Common Stock - Additional Paid in Capital including Option Reserve -34,119 -34,119 -34,119 -34,119 -34,119
Equity - Non-Contributed - Reserves & Retained Earnings 12,846,175 14,188,825 15,458,494 16,972,964 19,146,957
Retained Earnings - Total 12,787,858 14,073,109 15,361,121 16,875,671 18,746,849
Comprehensive Income - Accumulated - Total 97,750 113,517 113,831 124,326 88,474
Investments - Unrealized Gain/Loss 36,878 42,056 56,006 39,111 73,994
Foreign Currency Translation Adjustment - Accumulated 60,871 71,460 57,825 85,214 14,480
Other Reserves/Equity - Total -39,433 2,199.6 -16,457 -27,033 311,634
Common Equity - Total 13,280,807 14,623,458 15,893,126 17,405,533 19,579,526
Minority Interest - Equity 613,224 671,137 812,456 870,549 1,686,352
Total Shareholders' Equity
Total Shareholders' Equity - including Minority Interest & Hybrid Debt 13,894,032 15,294,595 16,705,582 18,276,082 21,265,878
Total Liabilities & Shareholders' Equity
Total Liabilities & Equity 16,616,239 18,146,206 20,264,727 22,564,300 25,666,635
Share/Per Share - Common
Common Shares - Issued - Total 46,875 46,875 46,875 46,875 46,875
Common Shares - Outstanding - Total 46,875 46,875 46,875 46,873 46,873
Common Shares - Treasury - Total 0 0 0 2.17 2.17
Common Shares - Authorized - Issue Specific 85,000 85,000 85,000 85,000 85,000
Common Shares - Issued - Issue Specific 46,875 46,875 46,875 46,875 46,875
Common Shares - Outstanding - Issue Specific 46,875 46,875 46,875 46,873 46,873
Common Shares - Treasury - Issue Specific 0 0 0 2.17 2.17
Share/Per Share - Other
Asset Allocation Factor - Issue Specific 1.00 1.00 1.00 1.00 1.00
Right of Use Tangible Assets
Right of Use Tangible Assets - Total - Net - Supplemental 152,382 107,911
Right of Use Tangible Assets - Capital/Finance Lease - Net - Supplemental 152,382 107,911
Right of Use Tangible Assets - Total - Gross - Supplemental 196,875 187,966
Right of Use Tangible Assets - Capital/Finance Lease - Gross - Supplemental 196,875 187,966
Right of Use Tangible Assets - Total - Accumulated Depreciation - Supplemental 44,493 80,056
Right of Use Tangible Assets - Capital/Finance Lease - Accumulated Depreciation - Supplemental 44,493 80,056
Property, Plant & Equipment - excluding Right of Use Tangible Assets & Capital Leases - Net 5,338,963 6,250,683 7,666,263 8,157,762 8,214,850
Property, Plant & Equipment - excluding Right of Use Tangible Assets & Capital Leases - Gross 8,151,171 9,400,848 11,185,277 12,108,320 12,593,091
Property, Plant & Equipment - excluding Right of Use Tangible Assets & Capital Leases - Accumulated 2,812,208 3,150,165 3,519,014 3,950,558 4,378,241
Depreciation
Right of Use Liabilities
Finance and Operating Lease Liabilities - Total 3,212.1 1,319.2 135.4 90,654 65,878
Debt including Finance and Operating Lease Liabilities 318,992 357,408 816,845 1,157,816 626,155
Long-Term & Short-Term
Investments - Total 239,881 242,024 258,745 262,019 386,404
Loans & Receivables - Total 2,996,192 3,427,915 3,750,346 3,630,173 3,588,719
Accounts & Notes Receivable - Trade - Gross - Total 2,898,394 3,281,251 3,600,695 3,501,113 3,455,599
Other Assets - Total 764,038 720,256 624,782 408,784 197,781
Income Taxes - Payable - Long-Term & Short-Term 190,793 188,122 226,517 428,878 351,590
Payables & Accrued Expenses 1,430,582 1,590,998 1,685,324 1,722,334 2,378,533
Trade Account Payables - Total 1,108,551 1,289,898 1,215,860 1,240,386 1,667,596
Accrued Expenses 322,031 301,100 469,464 481,949 710,937
Debt Related
Net Debt -2,652,209 -2,974,639 -2,419,260 -4,238,430 -5,849,016
Debt Maturity
Debt - Long-Term - Maturities - Total 846,662 560,277
Debt - Long-Term - Maturities - within 1 Year 123,843 70,000
Debt - Long-Term - Maturities - Year 5 722,819 490,277
Debt - Long-Term - Maturities - Remaining 0 0
Debt - Long-Term - Maturities - 4-5 Years 722,819 490,277
Debt - Long-Term - Maturities - Year 6 & Beyond 0 0
Capital Lease Maturity
Capital Lease Maturities - Total 135.4 90,654 65,878
Capital Lease Maturities - Due within 1 Year 94.51 24,921 23,646
Capital Lease Maturities - Due in Year 5 40.87 65,732 42,232
Capital Lease Maturities - Remaining Maturities 0 0
Capital Lease Maturities - Due in 4-5 Years 40.87 65,732 42,232
Capital Lease Maturities - Due in Year 6 & Beyond 0 0
Other
Minority Interest - Total 613,224 671,137 812,456 870,549 1,686,352
Accruals - Short-Term 5,031,909 5,208,793 5,604,895 4,690,676 5,961,306
Asset Accruals 13,803,035 14,938,533 17,171,554 17,321,124 19,406,811
Cash & Cash Equivalents - Total 2,784,706 3,153,328 3,040,487 5,207,929 6,216,248
Cash & Short Term Investments - Total 2,971,201 3,332,047 3,236,106 5,396,246 6,475,171
Debt - including Preferred Equity & Minority Interest - Total 932,216 1,028,545 1,629,301 2,028,365 2,312,507
Investments - Permanent 78,862 86,106 91,064 123,338 303,272
Net Book Capital 11,241,823 12,319,956 14,286,322 14,037,652 15,416,862
Net Operating Assets 11,241,823 12,319,956 14,286,322 14,037,652 15,416,862
Provisions - Total 339,469 291,722 334,347 322,940 333,092
Shareholders Equity - Common 13,280,807 14,623,458 15,893,126 17,405,533 19,579,526
Tangible Total Equity 13,474,459 14,861,154 16,043,029 17,616,064 20,133,147
Tangible Book Value 12,861,235 14,190,017 15,230,573 16,745,515 18,446,795
Total Book Capital 13,599,799 14,980,866 16,709,972 18,563,349 20,205,681
Total Capital 14,213,024 15,652,002 17,522,428 19,433,898 21,892,033
Total Long Term Capital 14,388,903 15,860,039 17,687,618 19,387,574 22,131,979
Total Fixed Assets - Net 6,543,790 7,443,572 8,989,550 9,453,722 9,910,850
Working Capital 7,816,614 8,362,121 8,645,382 9,898,606 12,177,553
Working Capital - Non-Cash 4,845,413 5,030,074 5,409,277 4,502,360 5,702,382
Working Capital excluding Other Current Assets & Liabilities 8,187,845 8,722,731 9,086,329 10,506,293 12,842,746
Book Value excluding Other Equity 13,320,241 14,621,258 15,909,584 17,432,566 19,267,892
Employees
Employees - Full-Time/Full-Time Equivalents - Period End 12,733 12,575 12,427 12,137 12,334
Employees - Full-Time/Full-Time Equivalents - Current Date 12,733 12,575 12,427 12,137 12,334
Company Fundamentals - Cash Flow
Company Name Kalbe Farma Tbk PT (KLBF.JK)
Country of Exchange Indonesia
Country of Headquarters Indonesia
TRBC Industry Group Pharmaceuticals
CF Template IND
Consolidation Basis Consolidated
Scaling Millions
Period Annual
Export Date 16-01-2023
Statement Data 2017 2018 2019 2020 2021
Period End Date 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Standardized Currency IDR IDR IDR IDR IDR
Cash Flow - Standardized (Currency: As Reported)
Field Name 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Operating Cash Flow - Direct
Cash Receipts - Business Activities - Cash Flow 21,749,972 22,705,217 24,423,134 25,453,548 28,936,595
Cash Payments - Business Activities - Cash Flow 12,759,012 13,404,946 15,046,414 15,295,694 18,765,992
Cash Payments - Suppliers of Goods & Services - Cash Flow 10,313,829 10,798,828 12,316,356 12,407,551 15,917,369
Cash Payments - Employees - Cash Flow 2,445,184 2,606,118 2,730,058 2,888,143 2,848,623
Income Taxes - Paid/(Reimbursed) - Cash Flow - Direct 751,411 835,148 818,595 592,189 965,742
Interest Paid - Cash - Direct 35,950 29,593 40,014 80,466 66,572
Interest & Dividends - Received - Total - Cash Flow - Direct 107,182 101,806 111,724 124,119 116,226
Cash Receipts/(Payments) - Net - Cash Flow -6,231,232 -5,694,347 -6,055,156 -5,344,116 -6,378,915
Net Cash Flow from Operating Activities 2,079,548 2,842,988 2,574,679 4,265,202 2,875,600
Investing Cash Flow
Capital Expenditures - Net - Cash Flow 1,212,755 1,356,680 1,967,785 1,095,734 979,418
Property, Plant & Equipment - Purchased/(Sold) - Net - Cash Flow 1,141,107 1,290,976 1,720,179 947,131 490,573
Property, Plant & Equipment - Purchased - Cash Flow 1,163,835 1,307,327 1,733,323 969,599 512,024
Property, Plant & Equipment Sold - Cash Flow 22,728 16,351 13,144 22,468 21,451
Intangible Assets - Purchased/(Sold) - Net - Total - Cash Flow 71,648 65,704 247,607 148,603 488,845
Intangible Assets - Purchased/Acquired - Cash Flow 71,648 65,704 249,604 148,605 488,845
Intangible Assets - Sold - Cash Flow 1,997.0 2.08 0
Capital Expenditures - Total 1,235,483 1,373,031 1,982,927 1,118,204 1,000,870
Acquisition & Disposals of Business - Assets - Sold/(Acquired) - Net - Cash Flow 0
Acquisition of Business - Cash Flow 0
Investments excluding Loans - Decrease/(Increase) - Cash Flow -7,990.5 4,819.2 -2,131.9 20,400 -57,741
Investment Securities - Unclassified - Sold/(Purchased) - Net - Total - Cash Flow -7,990.5 4,819.2 -2,131.9 20,400 -57,741
Investment Securities - Sold/Matured - Unclassified - Cash Flow 5,500.0 14,423 0.34 134,400 121,259
Investment Securities - Purchased - Unclassified - Cash Flow 13,491 9,603.7 2,132.3 114,000 179,000
Investments - Associated Companies & Joint Ventures - Sold/(Purchased) - Cash Flow -34,848 0 -71,085
Other Investing Cash Flow - Decrease/(Increase) -39,773 -7,500.0 0 -64,000
Net Cash Flow from Investing Activities -1,220,745 -1,391,634 -2,012,265 -1,075,334 -1,172,244
Financing Cash Flow
Dividends Paid - Cash - Total - Cash Flow 1,031,253 1,171,878 1,218,753 1,252,235 1,372,682
Dividends - Common - Cash Paid 1,031,253 1,171,878 1,218,753 1,252,235 1,372,682
Stock - Total - Issuance/(Retirement) - Net - Cash Flow -2,063.2 0
Stock - Issuance/(Retirement) - Net - Excluding Options/Warrants - Cash Flow -2,063.2 0
Stock - Common - Issuance/(Retirement) - Net - Cash Flow -2,063.2 0
Stock - Common - Repurchased/Retired - Cash Flow 2,063.2 0
Minority Interests & Joint Ventures - Net - Cash Flow 34,950 38,717 169,988 0
Debt - Long-Term & Short-Term - Issuance/(Retirement) - Total - Cash Flow 72,404 41,836 415,975 235,052 -533,194
Debt - Issued/(Reduced) - Short-Term - Total - Cash Flow 71,259 -96,080 37,000 70,862 -220,500
Debt - Issued - Short-Term - Cash Flow 584,496 414,896 95,526 689,535 136,100
Debt - Reduced - Short-Term - Cash Flow 513,238 510,976 58,526 618,673 356,600
Debt - Issued/(Reduced) - Long-Term - Cash Flow 1,145.9 137,916 378,975 164,190 -312,694
Debt - Issued - Long-Term - Cash Flow 6,977.1 143,000 507,000 431,000 0
Debt - Reduced - Long-Term - Cash Flow 5,831.2 5,084.0 128,025 266,810 312,694
Other Financing Cash Flow - Increase/(Decrease) -16,538 -18,739 -34,111 1,227,272
Net Cash Flow from Financing Activities -940,437 -1,110,064 -666,901 -1,019,246 -678,605
Non classified Cash Flow
Non-Classified Cash Flows -6,805.2 0
Foreign Exchange Effects
Foreign Exchange Effects - Cash Flow 8,659.7 26,952 -51,836 51,264 -16,433
Change in Cash
Net Change in Cash - Total -72,974 368,242 -156,324 2,215,081 1,008,318
Net Cash from Continuing Operations -72,974 368,242 -156,324 2,221,886 1,008,318
Net Cash - Beginning Balance 2,853,905 2,780,931 3,149,173 2,992,849 5,207,929
Net Cash - Ending Balance 2,780,931 3,149,173 2,992,849 5,207,929 6,216,248
Supplemental
Income Taxes - Paid/(Reimbursed) - Cash Flow - Supplemental 751,411 835,148 818,595 592,189 965,742
Interest Paid - Cash Flow - Supplemental 35,950 29,593 40,014 80,466 66,572
Interest & Dividends - Received - Cash Flow - Supplemental 107,182 101,806 111,724 124,119 116,226
Cash Dividends Paid & Common Stock Buyback - Net 1,254,298 1,372,682
Common Stock Buyback - Net 2,063.2 0
Free Cash Flow to Equity 939,198 1,528,144 1,022,868 3,404,520 1,362,987
Free Cash Flow Net of Dividends -187,187 298,079 -627,001 1,894,764 502,049
Free Cash Flow 844,065 1,469,957 591,752 3,146,998 1,874,730
Dividends Provided/Paid - Common 1,171,878 1,218,753 937,502 937,502

CF from Optg Activities before Change in WC & Int Payments 2,115,498 2,872,582 2,614,693 4,345,669 2,942,172
Company Fundamentals - Pension
Company Name Kalbe Farma Tbk PT (KLBF.JK)
Country of Exchange Indonesia
Country of Headquarters Indonesia
TRBC Industry Group Pharmaceuticals
CF Template IND
Consolidation Basis Consolidated
Scaling Millions
Period Annual
Export Date 16-01-2023
Statement Data 2017 2018 2019 2020 2021
Period End Date 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Standardized Currency IDR IDR IDR IDR IDR
Pension - Standardized (Currency: As Reported)
Field Name 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Funded Status
Funded Status - including Unfunded Plan Obligations -250,979 406,587 408,354 492,952 458,073
Funded Status 87,754 406,587 408,354 492,952 458,073
Funded Status - Total Pension 87,754 406,587 408,354 492,952 458,073
Plan Obligations - Unfunded 338,732
Plan Obligations - Unfunded - Total Pension 338,732
Fair Value of Plan Assets 978,898 1,101,236 1,239,988 1,422,474 1,412,669
Fair Value of Plan Assets - Total Pension 978,898 1,101,236 1,239,988 1,422,474 1,412,669
Projected Benefit Obligation - Total 891,144 694,649 831,634 929,522 954,595
Projected Benefit Obligation 891,144 694,649 831,634 929,522 954,595
Projected Benefit Obligation - Total Pension 891,144 694,649 831,634 929,522 954,595
Assumptions - Period-End
Discount Rate - Period End 7.3% 8.3% 7.3% 6.5% 6.5%
Discount Rate - Period End - Total Pension 7.3% 8.3% 7.3% 6.5% 6.5%
Compensation Rate - Period End 7.0% 5.0% 5.0% 5.0% 5.0%
Compensation Rate - Period End - Total Pension 7.0% 5.0% 5.0% 5.0% 5.0%
Income/Expense
Total Pension Plans - Total Pension & Post-Retirement 135,335 154,717 76,877 94,765 67,316
Total Pension Plan Expense - Total 135,335 154,717 76,877 94,765 67,316
Defined Benefit Income/Expense - Pension & Post-Retirement 135,335 154,717 76,877 94,765 67,316
Defined Benefit Income/Expense - Total Pension 135,335 154,717 76,877 94,765 67,316
Interest Cost 74,288 85,000 80,511 23,852 20,346
Interest Cost - Total Pension 74,288 85,000 80,511 23,852 20,346
Service Cost 130,714 137,584 92,881 111,096 104,167
Service Cost - Total Pension 130,714 137,584 92,881 111,096 104,167
Curtailments & Settlements -7,222.7 20,346
Curtailments & Settlements - Total Pension -7,222.7 20,346
Expected Return on Assets -69,667 -73,595 -96,515 -32,960 -35,139
Expected Return on Assets - Total Pension -69,667 -73,595 -96,515 -32,960 -35,139
Net Assets Recognized
Net Assets Recognized - Total Pension -250,979
Net Assets Recognized - Total Pension Plans -250,979
Company Fundamentals - Financial Summary
Company Name Kalbe Farma Tbk PT (KLBF.JK)
Country of Exchange Indonesia
Country of Headquarters Indonesia
TRBC Industry Group Pharmaceuticals
CF Template IND
Consolidation Basis Consolidated
Scaling Millions
Period Annual
Export Date 16-01-2023
Statement Data 2017 2018 2019 2020 2021
Period End Date 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Standardized Currency IDR IDR IDR IDR IDR
Financial Summary - Standardized (Currency: As Reported)
Field Name 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Selected Income Statement Items
Revenue from Business Activities - Total 20,182,120 21,074,306 22,633,476 23,112,655 26,261,195
Gross Profit - Industrials/Property - Total 9,559,165 9,557,022 9,840,365 9,857,664 10,927,699
Operating Profit before Non-Recurring Income/Expense 3,148,773 3,187,219 3,319,440 3,590,045 4,024,425
Earnings before Interest, Taxes, Depreciation & Amortization (EBITDA) 3,603,994 3,657,888 3,834,611 4,227,353 4,713,482
Income before Discontinued Operations & Extraordinary Items 2,453,251 2,497,262 2,537,602 2,799,623 3,232,008
Selected Balance Sheet Items
Cash & Cash Equivalents 2,784,706 3,153,328 3,040,487 5,207,929 6,216,248
Cash & Short-Term Investments 2,971,201 3,332,047 3,236,106 5,396,246 6,475,171
Total Assets 16,616,239 18,146,206 20,264,727 22,564,300 25,666,635
Debt - Total 318,992 357,408 816,845 1,157,816 626,155
Common Equity - Total 13,280,807 14,623,458 15,893,126 17,405,533 19,579,526
Selected Cash Flow Items
Net Cash Flow from Operating Activities 2,079,548 2,842,988 2,574,679 4,265,202 2,875,600
Capital Expenditures - Net - Cash Flow 1,212,755 1,356,680 1,967,785 1,095,734 979,418
Net Change in Cash - Total -72,974 368,242 -156,324 2,215,081 1,008,318
Free Cash Flow Net of Dividends -187,187 298,079 -627,001 1,894,764 502,049
Selected Per Share Data
Dividend Yield - Common Stock - Gross - Issue Specific - % 1.3% 1.6% 1.6% 1.8% 1.7%
Dividend Yield - Common Stock - Net - Issue Specific - % 1.1% 1.4% 1.4% 1.5% 1.5%
EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total 51.28 52.42 53.48 58.31 67.92
Shares used to calculate Diluted EPS - Total 46,875 46,875 46,875 46,873 46,873
Profitability / Return
Gross Profit Margin - % 47.4% 45.4% 43.5% 42.7% 41.6%
EBITDA Margin - % 17.9% 17.4% 16.9% 18.3% 18.0%
Operating Margin - % 15.6% 15.1% 14.7% 15.5% 15.3%
Income before Tax Margin - % 16.1% 15.8% 15.1% 15.7% 15.8%
Income Tax Rate - % 24.3% 24.8% 25.6% 23.0% 22.1%
Net Margin - % 12.2% 11.9% 11.2% 12.1% 12.3%
Free Cash Flow 844,065 1,469,957 591,752 3,146,998 1,874,730
Return on Average Common Equity - % (Income available to Common excluding Extraordinary Items) 19.1% 17.6% 16.4% 16.4% 17.2%
Return on Average Total Assets - % (Income before Discontinued Operations & Extraordinary Items) 15.4% 14.4% 13.2% 13.1% 13.4%
Return on Invested Capital - % 18.0% 16.6% 15.3% 15.1% 15.6%
Growth
Revenue from Business Activities - Total 20,182,120 21,074,306 22,633,476 23,112,655 26,261,195
Operating Profit before Non-Recurring Income/Expense 3,148,773 3,187,219 3,319,440 3,590,045 4,024,425
Earnings before Interest, Taxes, Depreciation & Amortization (EBITDA) 3,603,994 3,657,888 3,834,611 4,227,353 4,713,482
Income before Discontinued Operations & Extraordinary Items 2,453,251 2,497,262 2,537,602 2,799,623 3,232,008
EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total 51.28 52.42 53.48 58.31 67.92
Common Shares - Outstanding - Total 46,875 46,875 46,875 46,873 46,873
Financial Strength / Leverage
Total Debt Percentage of Total Assets 1.9% 2.0% 4.0% 5.1% 2.4%
Total Debt Percentage of Total Capital 2.2% 2.3% 4.7% 6.0% 2.9%
Total Debt Percentage of Total Equity 2.3% 2.3% 4.9% 6.3% 2.9%
Debt Service 52,256 29,270 26,399 193,488 166,149
Debt Service Percentage of Normalized after Tax Profit 2.1% 1.2% 1.0% 6.7% 5.1%
Interest Coverage Ratio 120.5 162.1 106.9 47.34 88.48
Dividend Coverage - % 205.1% 201.6% 267.4% 291.6% 242.6%
Earnings Retention Rate 0.51 0.50 0.63 0.66 0.59
Dividend Payout Ratio - % 48.8% 49.6% 37.4% 34.3% 41.2%
Enterprise Value Breakdown
Market Capitalization 79,242,323 71,250,186 75,937,698 69,375,181 75,703,322
Debt - Total 318,992 357,408 816,845 1,157,816 626,155
Minority Interest - Total 613,224 671,137 812,456 870,549 1,686,352
Cash & Short Term Investments - Total 2,971,201 3,332,047 3,236,106 5,396,246 6,475,171
Enterprise Value 77,203,338 68,946,683 74,330,894 66,007,300 71,540,658
Dupont / Earning Power
Asset Turnover 1.27 1.21 1.18 1.08 1.09
Income before Tax Margin - % 16.1% 15.8% 15.1% 15.7% 15.8%
Pretax ROA - % 20.4% 19.1% 17.8% 17.0% 17.2%
Total Assets to Total Shareholders Equity - including Minority Interest & Hybrid Debt 1.21 1.19 1.20 1.22 1.22
Pretax ROE - % 24.6% 22.8% 21.3% 20.8% 21.0%
Tax Complement 0.76 0.75 0.74 0.77 0.78
Return on Average Common Equity - % (Income available to Common excluding Extraordinary Items) 19.1% 17.6% 16.4% 16.4% 17.2%
Earnings Retention Rate 0.51 0.50 0.63 0.66 0.59
Reinvestment Rate - % 9.8% 8.9% 10.3% 10.8% 10.1%
Productivity
Net Income after Tax per Employee 192,646,073 197,349,610 202,991,907 227,945,165 264,150,029
Sales per Employee 1,584,838,051 1,665,426,441 1,810,533,266 1,881,831,541 2,146,311,513
Total Assets per Employee 1,304,974,430 1,443,038,262 1,630,701,445 1,859,133,255 2,080,966,042
Liquidity
Current Ratio 4.51 4.66 4.35 4.12 4.45
Quick Ratio 2.91 3.14 2.90 2.98 3.01
Working Capital to Total Assets 0.47 0.46 0.43 0.44 0.47
Operating
Accounts Receivable Turnover 7.09 6.65 6.40 6.34 7.36
Average Receivables Collection Days 51.63 55.06 57.17 57.74 49.76
Payables Turnover 9.63 9.73 10.35 10.93 10.67
Average Payables Payment Days 38.02 37.61 35.38 33.49 34.31
Inventory Turnover 3.12 3.32 3.59 3.66 3.57
Average Inventory Days 117.4 110.3 101.8 100.0 102.5
Average Net Trade Cycle Days 131.0 127.7 123.6 124.3 117.9
Company Fundamentals - Valuation
Company Name Kalbe Farma Tbk PT (KLBF.JK)
Country of Exchange Indonesia
Country of Headquarters Indonesia
TRBC Industry Group Pharmaceuticals
CF Template IND
Consolidation Basis Consolidated
Scaling Millions
Period Annual
Export Date 16-01-2023
Statement Data 2017 2018 2019 2020 2021
Period End Date 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Standardized Currency IDR IDR IDR IDR IDR
Valuation - Standardized (Currency: As Reported)
Field Name 31-12-2017 31-12-2018 31-12-2019 31-12-2020 31-12-2021
Enterprise Value
Enterprise Value 77,203,338 68,946,683 74,330,894 66,007,300 71,540,658
Enterprise Value, 5 Year Average 69,645,550 71,843,820 69,826,474 71,053,362 71,605,775
Market Capitalization
Market Capitalization 79,242,323 71,250,186 75,937,698 69,375,181 75,703,322
Market Capitalization, 5 Year Average 71,301,734 73,832,991 71,864,236 73,364,239 74,301,742
Price Close
Price Close (End of Period) 1,690.0 1,520.0 1,620.0 1,480.0 1,615.0
Price Close (End of Period), 5 Year Average 1,521.0 1,575.0 1,533.0 1,565.0 1,585.0
FOCF Yield
Free Cash Flow Yield - % 1.1% 2.1% 0.8% 4.5% 2.5%
Free Cash Flow Yield - %, 5 Year Average 1.4% 1.8% 1.6% 2.0% 2.1%
Dividend Yield
Dividend Yield - Common Stock - Net - Issue Specific - % 1.1% 1.4% 1.4% 1.5% 1.5%
Dividend Yield - Common Stock - Net - Issue Specific - %, 5 Year Average 1.1% 1.1% 1.2% 1.3% 1.4%
Dividend Yield - Common Stock - Gross - Issue Specific - % 1.3% 1.6% 1.6% 1.8% 1.7%
Dividend Yield - Common Stock - Gross - Issue Specific - %, 5 Year Average 1.3% 1.3% 1.5% 1.5% 1.6%
Price to Book
Price to Book Value per Share - Issue Specific 5.96 4.87 4.78 3.99 3.87
Price to Book Value per Share - Issue Specific, 5 Year Average 6.71 6.19 5.43 5.02 4.60
Price to Tangible Book
Price to Tangible Book Value per Share 6.16 5.02 4.99 4.14 4.10
Price to Tangible Book Value per Share, 5 Year Average 6.98 6.42 5.63 5.20 4.79
Price to Sales
Price to Revenue from Business Activities - Total per Share 3.93 3.38 3.36 3.00 2.88
Price to Revenue from Business Activities - Total per Share, 5 Year Average 3.93 3.85 3.55 3.45 3.28
Price to FOCF
Price to Free Cash Flow per Share 93.85 48.47 128.3 22.04 40.38
Price to Free Cash Flow per Share, 5 Year Average 70.82 56.12 63.90 51.03 46.86
Price to CF Per Share
Price to Cash Flow per Share 27.24 24.01 24.87 20.18 19.31
Price to Cash Flow per Share, 5 Year Average 27.73 27.19 25.36 24.20 22.81
Price to Diluted EPS
Price to EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total 32.96 29.00 30.29 25.38 23.78
Price to EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total, 5 Year Average 33.34 32.87 30.78 29.58 27.96
Price to Normalized Diluted EPS
Price to EPS - Diluted - excluding Extraordinary Items - Normalized - Total 32.96 29.00 30.29 24.50 23.78
Price to EPS - Diluted - excluding Extraordinary Items - Normalized - Total, 5 Year Average 6.71 6.19 5.43 5.02 4.60
PEG Ratio
PE Growth Ratio 7.30 13.02 15.00 2.81 1.44
PE Growth Ratio, 5 Year Average 0.71 6.49 7.81 4.62 4.16
EV to Sales
Enterprise Value to Revenue from Business Activities - Total 3.83 3.27 3.28 2.86 2.72
Enterprise Value to Revenue from Business Activities - Total, 5 Year Average 3.83 3.75 3.45 3.34 3.16
EV to EBITDA
Enterprise Value to Earnings before Interest, Taxes, Depreciation & Amortization (EBITDA) 21.42 18.85 19.38 15.61 15.18
Enterprise Value to Earnings before Interest, Taxes, Depreciation & Amortization (EBITDA), 5 Year Average 21.89 21.42 19.88 18.91 17.87
EV to CFO
Enterprise Value to Net Cash Flow from Operating Activities 37.13 24.25 28.87 15.48 24.88
Enterprise Value to Net Cash Flow from Operating Activities, 5 Year Average 34.46 29.95 28.51 25.38 24.46
EV to FOCF
Enterprise Value to Free Cash Flow 91.47 46.90 125.6 20.97 38.16
Enterprise Value to Free Cash Flow, 5 Year Average 69.18 54.61 62.09 49.43 45.16